Applications are open to interested applicants for the role of a Medical Officer/Research Assistant on a
WHO ACTION Trial for the Akure and Abuja study sites respectively.
WHO is currently conducting a clinical trial on the safety and efficacy of Antenatal Corticosteroids for Improving Newborn Outcomes (ACTION).
This is a multi-country, multi-center, two-arm, parallel, double-blind, placebo-controlled, randomized clinical trial of antenatal corticosteroids for women at risk of imminent birth in the early preterm period in hospitals in low-
resource countries to improve newborn outcomes.
There is important uncertainty as to whether
antenatal corticosteroids (ACS) are safe and/or
efficacious when used in facility settings in low-
Previous efficacy trials of ACS have not been conducted in resource-limited countries, and their safety and efficacy in these settings are not known despite their widespread use.
WHO is, therefore, co-ordinating the conduct of two concurrent trials on the efficacy of antenatal
corticosteroids in women at imminent risk of
preterm birth. The WHO Antenatal Corticosteroids
for Improving Outcomes in Preterm Newborns
(WHO ACTION) collaboration includes two trials:
A65913: ACTION-l Trial for women randomized in
the early preterm period (26 weeks O days gestation
to 33 weeks 6 days weeks gestation);
A65916: ACTION-ll Trial for women randomized in
the late preterm period (34 weeks O days to 36
weeks O days).
Study sites: 29 facilities in six sites from five
countries (Bangladesh, India, Kenya, Nigeria-lbadan,
Nigeria-lle Ife, and Pakistan) will participate in the
Interested applicants should be:
(1) Medical Officer of Health
(3) Strong commitment to clinical research and medicine.
(3) Must possess excellent team work approach.
(1) Interested applicants must be willing to work for an uninterrupted duration of 24 months. (This is a mandatory requirement)
(2) Working Closely with the Principal Investigator at the trial site to ensure that the trial is carried out according to the Research Protocol and all existing regulatory guidelines.
(3) Screening and randomization of eligible participants, follow-up till delivery, observation of the neontate at the Special care intensive unit at the trial hospital and follow-up of all trial participants.
(4) Ensuring completeness of the Case Record Forms (CRFs).
(5) Daily updates on all Trial Participants and working closely with all other research staff on the trial site.
(6) Protecting the rights and safety of all research/trial parricipants
(7) All other roles as specified by the Principal Investigator at the trial site.
Qualified applicants would work for a duration of 10 hours (Monday- Friday) and would take occasional weekend calls.
Qualified applicants would be on WHO permanent payroll for the duration of their employment.
Abuja Trial Site : N150,000
Akure Trial Site: N140,000
Qualified applicants would undergo training on the Manual of Operation (MOP) for the Research and the Research Protocol following which they would take the test on Good Clinical Practice (ICH-GCP) as prescribed by the International Council for Harmonization (ICH) for the conduct of Clinical Trials worldwide.
Only applicants who pass the GCP test would be certified by the National Institute on Drug Abuse (NIDA), USA and would be allowed to participate in the trial. The GCP test would be taken online after the training on the Manual of Operation is completed.
The certificate issued by NIDA-USA would last for three (3) years and would only be due for renewal upon expiry.
WHO would sponsor the training and all other expenses (transportation and feeding). The duration of the training would last for a period of 3-5 days.
Interested Applicants should forward their CV to Oluwatobiadegbile@gmail.com and prepare for an interview in earnest (likely online) with the lead Principal Investigator